The increased risk of transmission of COVID-19 infection causes the incidence of death in health workers to escalate. It requires further research on risk factors and intervention in health worker professionals, especially on immunity factors and nutritional status. Quality of diet and nutrition is very important to support the immune system when infected. Several probiotic strains have been shown to decrease the duration and incidence of diarrhea and respiratory infections, suggesting the Gut-Lung Axis pathway. Some probiotics also improve the balance of diversity in the composition of the gut microbiota and affect body weight in obese people. Probiotics have also been shown to improve vitamin D absorption. A combination of vitamin D and probiotics may be an alternative to reduce gut dysbiosis that will directly or indirectly reduce the risk and severity of viral infections including SARS-CoV-2.
Obesity is increasing in Indonesia and is the cause of various diseases, especially in the
presence of Vitamin D deficiency, a state of dysbiosis, causing an increase in the
possibility of infection. Professional health workers have a high risk of COVID-19 due to
high daily exposure. Based on a review conducted by Daniel et al, it was found that 7.3% of
health workers at Reutters University tested positive for COVID-19. Based on data from the
Indonesian Doctors Association (IDI) on July 12, 2020, it was known that 61 doctors had died.
In addition, based on data from the Indonesian National Nurses Association (PPNI), 39 nurses
have died during the COVID-19 pandemic. Therefore efforts to prevent the occurrence of
COVID-19 infection by providing a combination of vitamin D and probiotics to modulate
dysbiosis that will further reduce the risk of viral infection, especially COVID-19, needs to
be investigated for its potential benefits.
Primary and secondary objectives
1. Primary Objective:
To investigate the effect of a combination of probiotics and vitamin D supplementation
in modulating intestinal dysbiosis, and vitamin D status, in people with overweight and
obesity, especially among frontline health workers.
- To assess the mean changes in zonulin levels (as a parameter of gut integrity to
indicate the intestinal microbiota dysbiosis)
- To assess the mean changes in serum vitamin D levels
2. Secondary Objectives:
- To assess the relationship between nutritional status, inflammation and immunity
with the risk of COVID-19 infection in health workers.
- To understand the difference in the mean episodes of Covid-19 infection between
treatment and placebo groups after giving probiotics and vitamin D in people with
overweight and obesity, especially among frontline health workers.
Study Design:
This study has 2 phases Phase 1: a Cross-sectional study with 160 people Phase 2: a
double-blind, randomized, placebo-controlled trial with two arms of intervention involving a
total of 80 people.
Dietary Supplement: Probiotics, Vitamin D
Combination of two supplement that given separately
Other: Placebo
Placebo with inactive ingredient
Inclusion Criteria:
- General doctors, specialist doctors, nurses and midwives who are in charge of handling
COVID-19 patients or working in COVID-19 referral hospitals for at least the last 3
months
- 20-65 years old
- Willing to sign informed consent
- Willing to follow the research to completion
- BMI > 23 kg/m2
Exclusion Criteria:
- Pregnant woman
- Have a confirmed history of COVID-19 based on previous PCR examinations
- Suffering from acute illness known from history and physical examination or chronic
disease (eg diabetes, SLE, cardiovascular disease) known from history
- Currently not on a diet program for weight loss or consuming probiotics regularly in
the last 3 months as known from the anamnesis
Department of Nutrition (FKUI-RSCM); and Human Nutrition Research Center, Indonesian Medical Education Research Institute (HNRC-IMERI) Faculty of Medicine, Universitas Indonesia
Jakarta Pusat, DKI Jakarta, Indonesia
Dr.Cipto Mangunkusumo General Hospital (RSCM)
Jakarta Pusat, DKI Jakarta, Indonesia
Wisma Emergency COVID-19 Hospital (RSDC)
Jakarta, DKI Jakarta, Indonesia
University of Indonesia Hospital (RSUI)
Depok, West Java, Indonesia
Rina Agustina, MD, PhD
+62213912477
dr.rinaagustina@gmail.com
Yani Kurniawan, MD, MM,
+62213912477
Rina Agustina, MD, PhD, Principal Investigator
HNRC-IMERI, Faculty of Medicine Universitas Indonesia